This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Anthrax toxin receptor 1 (ANTXR1; TEM8)	<p>Studies in mice suggest inhibiting TEM8 could help treat cancer. In multiple mouse models of cancer, injection of an anti-TEM8 antibody decreased tumor growth compared with vehicle control injection. The effect of the anti-TEM8 antibody was increased when co-injected with an anti-VEGF receptor 2 (KDR/Flk-1; VEGFR-2) antibody or the generic chemotherapeutics 5-fluorouracil (5-FU) or irinotecan. Next steps at the National Cancer Institute include examining the TEM8-expressing cell types that are important for promoting tumor growth and testing TEM8 antibodies for imaging tumor angiogenesis. Novartis AG, which collaborated on the project, did not disclose its next steps.</p> <p>SciBX 5(10); doi:10.1038/scibx.2012.249 Published online March 8, 2012</p>	Patent application filed; licensing status undisclosed	<p>Chaudhary, A. <i>et al. Cancer Cell</i>; published online Feb. 13, 2012; doi:10.1016/j.ccr.2012.01.004</p> <p>Contact: Brad St. Croix, National Cancer Institute, Bethesda, Md. e-mail: stcroix@ncifcrf.gov</p>